Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for MDD and BPD
NCT05399498Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD) and borderline personality disorder (BPD), sponsored by University of Chicago. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 5 weeks and Borderline Personality Disorder Symptom Assessment Scale at 5 weeks. Started Nov 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT05399498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399498.